SREBF1 and metabolic dysfunction-associated steatotic liver disease: In patients with NAFLD, treatment with antrodan, which is used to treat alcohol-associated steatohepatitis, alleviates fatty liver symptoms and liver injuries by altering AMPK–Sirt1–PPARγ–SREBP-1c signaling, although the mechanism is not clear [36].